newsfilter
← Latest News
GlobeNewswire·

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's diseaseSimufilam continued to demonstrate an overall